Doubled Survival Rates For High Risk (Ph+ALL) Leukemia With Novel Imatinib Treatment

Outcomes of the Phase II clinical trials printed in the 5th October edition of the Journal of Clinical Oncology reveals that including continual every day dosages of the targeted drug known as imatinib mesylate to standard chemotherapy showed a greater than two folds rise in survival rates in infants having a high risk form of blood cancer known as Philadephia chromosome-positive acute lymphoblastic leukemia or Ph+ALL thus proving to be a path-breaking revelation in the field of leukemia research.

The Children’s Oncology Group conducted the study in about twenty N. American centres helmed by Dr. Kirk Schultz, who heads the childhood cancer research at the Child & Family Research Institute (CFRI) and a paediatric oncologist from the BC Children’s Hospital, an agency of the Provincial Health Services Authority.

Dr. Kirk Schultz explained that on using standard chemotherapy there was a 3-year survival rate of 30-35% among infants having this high-risk form of leukemia. But when continual imatinib exposure was added, a major change was observed with survival rates rising to 87%. The drug was easily tolerated by the children and it had no major side effects. Survival rates are the span of time during which a person survived facing no recurrence and did not develop a new form of cancer.

There are several forms of acute lymphoblastic leukemia and each of them tends to respond in varying ways to treatment. Ph+ALL occur due to heritable anomalies on two particular chromosomes.

As standard chemotherapy fails to be beneficial among several infants having Ph+ALL, the standard line of treatment is transplantation of blood and bone marrow – a life-giving practice that is linked with a risk of developing complications.

Dr. Schultz elucidated that by employing the targeted drug imatinib alongside standard chemotherapy, the outcomes indicate that they were able to enhance survival levels to such an extent that blood and marrow transplants would no longer be needed. Delving deeper into the inheritance of cancers allowed the researchers to ascertain the idyllic approach for treating each infant and become increasingly discerning about the apt usage of costly medications.

Imatinib available commercially as Gleevec is a tablet that is utilised for the treatment of some forms of adult leukemias and gastrointestinal cancer. It is known to fasten to certain protein in cancerous cells and avert cells from proliferation.

Joint networks like the Children’s Oncology Group are vital for the recruitment of ample numbers of entrants for the trial of novel treatments for rare forms of diseases like Ph+ALL that is detected in nearly 6 kids and ninety adults annually in Canada.

During the course of this study, 92 infants and adolescents in the age groups ranging from 1 to twenty-one  years having Ph+ALL were entrants and each were given the initial one month of standard chemotherapy. They are allotted to 5 varied sets that were given imatinib for varying time spans like 42, 63, 84,126 or 280 days. All the entrants were given an added 336 days of imatinib.

The set that was administered imatinib for further than 280 uninterrupted days showed 87% survival rates, a drastic enhancement over standard chemotherapy and blood and marrow transplantation. Sets that were given imatinib for time spans of 86 and 126 days exhibited moderate levels of enhancement in their survival rates, whereas sets that received the drug for time periods of 42 and 63 days showed similar survival rates as the present conventional treatments. There were additionally 21 entrants having Ph+ALL that underwent treatment with blood and marrow transplantation followed by 6 months of the drug imatinib. This strategy seemed to show no effect on the survival rates.

Dr. Schutz concluded that when imatinib was employed along with chemotherapy, it had a synergising form of interface with unexpected outcomes. Though the results show immense potential, the researchers believe that further follow up is required for getting the 5-year survival information and for ascertaining the long-lasting survival.

The researchers are presently planning on getting started with the phase III of the study for validating whether the addition of imatinib with chemotherapy could effectively substitute blood and marrow transplantation as the standard line of treatment for Ph+ALL.

Popularity: 33% [?]